bid i p bi1347 (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
94
Structured Review
MedChemExpress
bid i p bi1347
Bid I P Bi1347, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bid i p bi1347/product/MedChemExpress
Average 94 stars, based on 4 article reviews
Bid I P Bi1347, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bid i p bi1347/product/MedChemExpress
Average 94 stars, based on 4 article reviews
bid i p bi1347 - by Bioz Stars,
2026-02
94/100 stars
Images
1) Product Images from "CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS G12D inhibition in pancreatic ductal adenocarcinoma"
Article Title: CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS G12D inhibition in pancreatic ductal adenocarcinoma
Journal: bioRxiv
doi: 10.1101/2025.01.29.635543
Figure Legend Snippet: CDK8 and CXCR2 inhibition reverses MRTX1133 resistance. ( A ) Schematic of orthotopic PKC-HY19636 tumors treated with MRTX1133, CDK8i (BI1347), and CXCR2i (SB22502). ( B ) Survival curve of orthotopic PKC-HY19636 mice. Vehicle, n=12; CDK8i, n=12; CXCR2i, n=12; MRTX1133, n=12; MRTX1133+CDK8i, n=12; MRTX1133+ CXCR2i, n=12. Survival experiment was terminated shortly after all the MRTX1133 treated mice reached endpoints. ( C ) Tumor/pancreas weights at 1-week post-treatment. Vehicle, n=5; CDK8i, n=9; CXCR2i, n=9; MRTX1133, n=5; MRTX1133+CDK8i, n=6; MRTX1133+ CXCR2i, n=5. ( D ) Representative H&E, pERK, CDK8, and CD206 staining at 1-week post-treatment. ( E ) Weighted histology score. Vehicle, n=6; CDK8i, n=5; CXCR2i, n=7; MRTX1133, n=5; CDK8i+MRTX1133, n=3; CXCR2i+MRTX1133, n=5. ( F-H ) Quantification of pERK ( F ), CDK8 ( G ), and CD206 ( H ) staining. pERK: Vehicle, n=5; CDK8i, n=5; CXCR2i, n=5; MRTX1133, n=5; CDK8i+MRTX1133, n=4; CXCR2i+MRTX1133, n=5. CDK8: Vehicle, n=5; CDK8i, n=3; CXCR2i, n=4; MRTX1133, n=4; CDK8i+MRTX1133, n=4; CXCR2i+MRTX1133, n=3. CD206: Vehicle, n=5; CDK8i, n=5; CXCR2i, n=6; MRTX1133, n=5; CDK8i+MRTX1133, n=3; CXCR2i+MRTX1133, n=5. ( I-J ) Representative H&E ( I ) and weighted histology score ( E ) of murine pancreata at endpoint. MRTX1133, n=5; CDK8i+MRTX1133, n=8; CXCR2i+MRTX1133, n=7. ( K-L ) Representative images ( K ) and quantified tumor volume measured by MRI ( L ). Yellow lines demarcate tumor regions. Vehicle, n=7; CDK8i, n=7; CXCR2i, n=7; MRTX1133, n=6; CDK8i+MRTX1133, n=8; CXCR2i+MRTX1133, n=8. Gehan-Breslow-Wilcoxon test performed in (B). Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test performed in (C). One-way ANOVA with Dunnett’s multiple comparisons test performed in (G) and (H). Kruskal-Wallis with Dunn’s multiple comparisons test performed in (E) and (F). Two-way ANOVA with Dunnett’s multiple comparisons test performed in (L). Scale bars, 100 μm. Data are presented as mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns : not significant.
Techniques Used: Inhibition, Staining
Figure Legend Snippet: Resistance to MRTX1133 leads to loss of antigen presentation which can be reversed with inhibition of CDK8. ( A ) Expression of antigen presentation genes of ductal/cancer cells of PKC-HY19636 tumors compared to vehicle treated mice as determined by scRNA-seq analysis. ( B-C ) Representative CODEX images of CD3, CD8α, CD4, and TCRβ ( B ) and quantification of cell abundance per tissue area of PKC-HY19636 orthotopic tumors ( C ). Scale bars, 250 μm. ( D ) Schematic of orthotopic PKC-HY19636 tumors treated with MRTX1133 and αCTLA4. ( E ) Survival curve of orthotopic PKC- HY19636 mice. Vehicle, n=3; αCTLA4, n=4; MRTX1133, n=5; MRTX1133+ αCTLA4, n=6. ( F-H ) Representative images ( F ) and quantification of FAS - CDK8 + CK19 + ( G ) and FAS + CDK8 - CK19 + ( H ) cells in orthotopic PKC-HY19636 tumors. MRTX1133 sensitive, n=2; MRTX1133 resistant, n=3; MRTX1133+⍺CTLA-4 early, n=3; MRTX1133+⍺CTLA-4 late, n=3. Scale bar, 50 μm. ( I ) Schematic of orthotopic PKC-HY19636 tumors treated with MRTX1133, CDK8i (BI1347), and αCTLA-4. ( J-K ) Representative images ( J ) and quantified tumor volume measured by MRI relative to tumor volume at 2 weeks following MRTX1133 treatment initiation ( K ). Yellow lines demarcate tumor regions. MRTX1133, n=9; MRTX1133+αCTLA-4, n=6; MRTX1133+CDK8i, n=7; MRTX1133+CDK8i+αCTLA-4, n=7. ( L ) Survival curve of orthotopic PKC-HY19636 mice. MRTX1133, n=10; MRTX1133+αCTLA-4, n=8; MRTX1133+CDK8i, n=11; MRTX1133+CDK8i+αCTLA-4, n=10. ( M ) UMAP of T and NK cells of orthotopic PKC-HY19636 tumors determined by scRNA-seq. Pancreata/tumors from 3 mice pooled per group. ( N ) Overall abundance of T and NK cell subsets in PKC-HY19636 determined by scRNA-seq. Kruskal-Wallis with Dunn’s multiple comparisons test performed for CD3 TCRβ in (C), one-way ANOVA with Dunnett’s multiple comparisons test performed for CD4 TCRβ and CD8 TCRβ in (C), and log-rank test performed in (E and L). One-way ANOVA with Dunnett’s multiple comparisons test performed in (G), (H). Dunnett’s multiple comparisons test performed in (K). * P < 0.05, ** P < 0.01, **** P < 0.001, ns : not significant.
Techniques Used: Inhibition, Expressing